Humacyte, Inc. is a regenerative medicine company developing a pioneering biotechnology platform for universally implantable, off-the-shelf bioengineered human tissues and organs. These acellular tissue-engineered products aim to treat a broad spectrum of diseases, injuries, and chronic conditions by providing regenerative solutions that minimize immune rejection and infection risks. Key offerings include the Acellular Tissue Engineered Vessel for vascular repair and bypass procedures, such as in vascular trauma, peripheral arterial disease, arteriovenous access for hemodialysis, and pediatric heart surgery. The company also advances organ systems and advanced tissue constructs, including preclinical adaptations for vascularized pancreas constructs, lung constructs, urinary conduits, tracheal, and esophageal replacements. Humacyte supports healthcare professionals with product-related medical information, clinical education, peer-to-peer resources, and operational training for investigational products. Expertise spans regenerative medicine, tissue engineering, biomanufacturing scale-up, decellularization, and preclinical modeling. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte focuses on transforming medical practices through accessible tissue repair and replacement technologies.